PCVX
USDVaxcyte Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$35.130
Kõrge
$35.390
Madal
$34.260
Maht
0.89M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
4.4B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
2.50M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today
Cantor Fitzgerald Initiates Coverage On Vaxcyte with Overweight Rating
Cantor Fitzgerald analyst Carter Gould initiates coverage on Vaxcyte with a Overweight rating.
Seotud aktsiad
LCTX
Lineage Cell Therapeutics Inc.
SKX
Skechers U.S.A. Inc.
AGNCO
AGNC Investment Corp. Depositary Shares each representing a 1/1000th interest in a share of 6.50% Series E Fixed-to-Floating Cumulative Redeemable Preferred Stock
MYI
Blackrock MuniYield Quality Fund III Inc
ILMN
Illumina Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.